NCT04557228Completed
ADAM17 and Vascular Function in Diabetes
Targeting ADAM17 Activity for Correction of Vascular Insulin Resistance in Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 4 May 2026
Brief summary (registry, in English)
The objective of this project is to determine the extent to which administration of the dietary supplement phosphatidylserine (PS), a competitive inhibitor of ADAM17 sheddase activity, effects vascular function and insulin-stimulated leg blood flow in subjects with T2D.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 36 (actual)
- First submitted
- 8 Sept 2020
- Start date
- 1 Mar 2023
- Primary completion date
- 3 Feb 2025
- Lead sponsor
- University of Missouri-Columbia
- Diseases
- Type 2 diabetes
- NCT number
- NCT04557228
What you commit to
- Study type: Interventional
- Participants enrolled: 36
- From 1 Mar 2023 to the primary completion date, 3 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Immunosuppressant therapy
- Hormone replacement therapy
Other illness
- Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke
- History of chronic renal or hepatic disease
- Active cancer
- Autoimmune diseases
Other
- Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
- Current tobacco use
- Pregnancy
- Bodyweight change ≥5% within the last 6 months
Who the study is looking for
- Men and women with a BMI of 25-39 kg/m2, who are 45-64 years of age at randomization.
- T2D patients classified based on physician diagnosis.
- No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.
Age in the registry: 45 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Missouri- NextGen Clinical Translational Science Unit Coordinator of this site? Confirm its status | Columbia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.